FluoroPharma Medical, Inc. announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue (18) F-FCPHA at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% |
|
0.00% | 0.00% |
2022 | FluoroPharma Medical, Inc. Announces Executive Changes | CI |
2022 | FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.76T | |
+24.66% | 4.8TCr | |
+0.43% | 4.24TCr | |
+43.96% | 4.15TCr | |
+26.17% | 3.16TCr | |
+20.25% | 2.86TCr | |
-4.47% | 2.8TCr | |
+51.68% | 1.46TCr | |
+44.57% | 1.41TCr | |
+2.01% | 1.26TCr |
- Stock Market
- Equities
- FPMI Stock
- News FluoroPharma Medical, Inc.
- Fluoropharma Medical, Inc. Presents Data from Phase II Clinical Trial of 18F FCPHA